What Is Peptide Therapy? A Comprehensive Guide to Therapeutic Peptides in Longevity Medicine
AUTHOR
Aerwell
SHARE
PPeptides have become an increasingly important area of research and clinical interest in longevity and precision medicine. These short chains of amino acids serve as signaling molecules throughout the body, influencing processes ranging from hormone signaling and metabolism to immune function and tissue repair.
Some peptide-based medications are well established and FDA-approved for specific medical conditions. Others being studied or used in longevity medicine have more limited human evidence, may be prescribed off-label when appropriate, or remain investigational.
At Aerwell, peptide therapy is considered within this broader context. Rather than viewing peptides as a single treatment category, we evaluate individual therapies based on their mechanism of action, available clinical evidence, safety profile, regulatory status, and relevance to a patient’s health and goals.
This guide explains what peptides are, how they work, why they have generated interest in longevity medicine, and what patients should understand about their potential benefits, limitations, and risks.
What Are Peptides?
Peptides are chains of amino acids, the same building blocks that make up proteins. They are generally shorter than proteins and often function as signaling molecules that allow cells and tissues to communicate.
The human body naturally produces hundreds of peptides. They participate in numerous physiological processes, including:
- Hormone signaling
- Metabolism and glucose regulation
- Appetite and satiety
- Immune function
- Inflammation
- Tissue repair
- Cardiovascular function
- Growth and development
Some of the most familiar medications used today are peptide-based or peptide-related therapies. Therapeutic peptides may reproduce or modify the activity of naturally occurring signaling molecules. By interacting with specific receptors and biological pathways, they can potentially influence physiological processes with a relatively targeted mechanism of action.
Importantly, however, the term “peptide therapy” encompasses many different compounds. Their mechanisms, clinical evidence, safety profiles, and regulatory status vary considerably. Evidence supporting one peptide should not automatically be generalized to another.
How Peptide Therapy Works
Receptor Binding and Cellular Signaling
Many peptides work by binding to specific receptors on the surface of cells. This interaction can initiate intracellular signaling pathways that influence hormone secretion, gene expression, enzyme activity, metabolism, inflammation, or other cellular processes.
Certain peptides, for example, interact with receptors involved in the body’s growth hormone signaling pathways. Rather than supplying growth hormone directly, some therapies can stimulate endogenous hormone secretion through signaling at the hypothalamic or pituitary level.
Other peptides are being investigated for their interactions with pathways involved in tissue repair, immune regulation, metabolism, or mitochondrial function. The biological specificity of these signaling pathways is one reason peptides have attracted considerable interest in precision and longevity medicine.
Supporting Cellular Communication
Aging is associated with changes in cellular signaling, hormone production, mitochondrial function, immune regulation, inflammatory activity, and tissue-repair capacity.
Researchers are studying whether targeting some of these signaling pathways could influence aspects of age-related physiological decline. Peptide-based therapies are particularly interesting in this context because certain peptides interact with pathways that become altered with aging.
However, demonstrating an effect on a biological pathway is not the same as demonstrating that a therapy slows aging or extends lifespan. For many peptide therapies used or investigated in longevity medicine, those larger clinical questions remain unanswered.
Aging, Peptide Signaling, and Healthspan
Numerous signaling systems change throughout adulthood. Growth hormone and IGF-1 signaling, for example, change significantly with age. The thymus undergoes involution, immune function changes, mitochondrial efficiency can decline, and the body’s ability to recover from injury may decrease.
These changes contribute to familiar features of aging, including:
- Loss of muscle mass and strength
- Changes in body composition
- Reduced recovery capacity
- Altered immune function
- Changes in glucose metabolism
- Reduced tissue-repair capacity
Because peptides participate in many of these signaling systems, researchers have investigated whether specific peptide therapies can modify particular age-associated pathways.
This is an evolving area of medicine. Some peptide-based therapies have substantial human clinical evidence for defined indications, while others have primarily mechanistic, animal, or early-stage human data.
At Aerwell, the strength of the evidence for the specific therapy being considered matters more than the general category of “peptides.”
Key Areas of Peptide Research in Longevity Medicine
Growth Hormone Signaling
One area of interest involves peptides and related compounds that influence the hypothalamic-pituitary-growth hormone axis.
Certain therapies can stimulate endogenous growth hormone secretion through growth hormone-releasing hormone, ghrelin-receptor, or related signaling pathways. Growth hormone and IGF-1 participate in muscle protein synthesis, body composition, bone metabolism, and tissue repair.
Clinical research has demonstrated that some growth hormone secretagogues can increase pulsatile growth hormone secretion and IGF-1 concentrations in older adults. Research has also explored their effects on body composition and other age-associated physiological changes.
However, restoring or increasing GH/IGF-1 signaling should not automatically be interpreted as an anti-aging benefit. The long-term balance of potential benefits and risks remains an important consideration, and effects observed with one agent cannot necessarily be generalized to others.
Potential benefits and risks depend heavily on the specific medication and patient. These therapies require thoughtful patient selection and monitoring.
Tissue Repair and Recovery
Another area of peptide research involves pathways associated with tissue repair, angiogenesis, inflammation, cell migration, and gastrointestinal barrier function.
Preclinical research involving certain investigational peptides has demonstrated effects on pathways involved in wound healing and tissue recovery. These findings have generated considerable interest in sports medicine, musculoskeletal recovery, and regenerative medicine.
However, evidence from laboratory or animal studies should not be interpreted as proof of clinical effectiveness in humans. For several peptides discussed in regenerative and longevity medicine, adequately powered randomized human trials remain limited or absent.
Their potential clinical applications therefore need to be considered in the context of the available evidence and regulatory status of each individual therapy.
Immune Signaling
Peptides also play important roles in immune communication. Certain peptide pathways influence T-cell function, cytokine signaling, immune-cell maturation, and inflammatory responses.
Researchers have investigated peptide-based interventions in areas ranging from immune dysfunction and infectious disease to age-associated changes in immune function.
This area is particularly relevant to longevity research because aging is associated with thymic involution, changes in adaptive immunity, and chronic low-grade inflammatory activity.
Some immune-modulating peptides have been studied clinically in specific populations and conditions, while evidence for their use specifically to improve healthspan or counter immunosenescence remains much less established.
Human evidence varies substantially among individual therapies, and immune-modulating effects observed experimentally do not necessarily translate into clinically meaningful improvements in immunity, infection risk, or longevity.
Mitochondrial Function and Metabolic Health
Mitochondrial dysfunction is one of the biological processes associated with aging and metabolic disease.
A growing area of research focuses on mitochondrial-derived and mitochondrial-targeted peptides involved in cellular stress responses, energy metabolism, insulin sensitivity, oxidative stress, and communication between mitochondria and the rest of the cell.
Research involving mitochondrial-derived peptides has identified potentially important relationships with metabolism, cellular senescence, inflammation, cardiovascular function, and other age-associated processes.
Much of this evidence remains preclinical or observational. While some mitochondrial-targeted peptide therapies have progressed into human clinical research, it has not been established that targeting these pathways slows human aging or extends lifespan.
This remains a promising but evolving area of longevity science.
Peptides and the Hallmarks of Aging
Researchers have proposed a framework of interconnected biological processes known as the hallmarks of aging to help explain how aging occurs at the cellular and molecular level.
The updated framework includes 12 hallmarks:
- Genomic instability
- Telomere attrition
- Epigenetic alterations
- Loss of proteostasis
- Disabled macroautophagy
- Deregulated nutrient sensing
- Mitochondrial dysfunction
- Cellular senescence
- Stem-cell exhaustion
- Altered intercellular communication
- Chronic inflammation
- Dysbiosis
Peptide signaling intersects with several pathways involved in these hallmarks. For example, some peptide pathways influence mitochondrial function, inflammatory signaling, growth-factor activity, metabolic regulation, and cellular communication.
This creates an important area for research. It is also important to distinguish mechanism from outcome. A therapy that influences a pathway associated with a hallmark of aging has not necessarily been shown to reverse that hallmark, prevent age-related disease, or extend human lifespan.
For this reason, Aerwell approaches peptide therapy as one potential component of individualized longevity medicine rather than as a treatment for aging itself.
FDA Approval, Compounding, and Regulatory Status
The regulatory status of peptide therapies varies substantially. Some peptide medications are FDA-approved for specific medical conditions. FDA-approved medications may sometimes also be prescribed off-label when a licensed clinician determines that doing so is medically appropriate.
Other peptides discussed in longevity or regenerative medicine are investigational and have not been approved by the FDA for the purposes for which they are sometimes promoted.
Compounded medications represent another distinct category. Compounded drugs are not FDA-approved, and the FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before they are marketed in the same manner as FDA-approved pharmaceutical products.
Federal and state laws also determine which substances may be compounded, under what circumstances, and by which types of pharmacies or outsourcing facilities. The regulatory status of individual peptide ingredients can change as FDA policies evolve.
For these reasons, the fact that a substance is a peptide—or that it can be obtained from a pharmacy—does not by itself establish that it is FDA-approved, appropriate for compounding, or supported by adequate clinical evidence.
When peptide therapy is considered at Aerwell, the regulatory status, evidence, potential risks, and sourcing of the specific therapy are evaluated as part of the clinical decision-making process.
Patients should be particularly cautious about peptides purchased from websites selling products labeled “for research use only.” Products obtained outside legitimate medical and pharmacy channels may have uncertain identity, purity, potency, sterility, or quality.
Peptide Therapy as Part of a Broader Longevity Strategy
Peptide therapy should not replace the interventions with the strongest evidence for improving long-term health.
Understanding how peptide therapy compares to other longevity modalities helps clarify its role in a comprehensive longevity protocol.
| Intervention | Mechanism | Evidence Level | Best For |
|---|---|---|---|
| Peptide Therapy | Signaling molecule restoration; receptor activation | Moderate (growing) | Tissue repair, GH optimization, gut health |
| Hormone Replacement (TRT/HRT) | Direct hormone supplementation | Strong | Documented hormone deficiency |
| Metformin / Rapamycin | mTOR/AMPK pathway modulation | Moderate | Metabolic aging and longevity |
| NAD+ Precursors (NMN/NR) | NAD+ pathway restoration | Moderate | Mitochondrial function, energy metabolism |
The foundations of longevity medicine remain:
- Regular resistance and aerobic exercise
- Adequate sleep
- High-quality nutrition
- Maintenance of muscle mass and cardiorespiratory fitness
- Appropriate body composition
- Blood-pressure control
- Optimization of lipids and metabolic health
- Avoidance of tobacco
- Appropriate cancer and cardiovascular screening
- Meaningful social connection and psychological well-being
When appropriate, medical therapies may be layered onto these foundations based on an individual’s health risks, laboratory findings, symptoms, and goals.
Peptides may represent one such tool for selected patients. They should be considered alongside—not instead of—well-established preventive and therapeutic interventions.
What to Expect in a Peptide Therapy Consultation
At Aerwell, consideration of peptide therapy begins with an individualized medical assessment. This may include review of:
- Medical and family history
- Current medications and supplements
- Previous medical treatments
- Cardiometabolic health
- Hormonal status when relevant
- Exercise and recovery
- Sleep
- Body composition
- Current symptoms
- Personal health and performance goals
Laboratory testing may be recommended depending on the therapy being considered. Testing could include metabolic markers, kidney and liver function, blood counts, lipids, glucose regulation, thyroid function, hormone markers, or inflammatory markers when clinically appropriate.
There is no universal laboratory panel required for every peptide therapy. Testing and monitoring should be selected according to the medication, the patient’s underlying health, and the potential risks of treatment.
If a therapy is considered appropriate, the clinician should discuss:
- Why the therapy is being considered
- The strength and limitations of the available evidence
- Whether the proposed use is FDA-approved, off-label, compounded, or investigational
- Potential benefits
- Known and uncertain risks
- Alternative approaches
- Administration and dosing
- Appropriate monitoring
- Circumstances in which treatment should be stopped
The decision to use a peptide should ultimately be individualized rather than based on a predetermined “peptide protocol.”
Safety and Potential Side Effects
There is no single safety profile for peptide therapy. Potential adverse effects vary significantly depending on the specific medication, dose, route of administration, duration of treatment, and individual patient.
Depending on the therapy, potential effects may include:
- Injection-site reactions
- Headache
- Dizziness
- Fluid retention
- Changes in appetite
- Changes in glucose metabolism
- Hormonal effects
- Allergic or hypersensitivity reactions
Other risks may be specific to an individual peptide or signaling pathway. Long-term safety data are limited for some investigational peptide therapies.
This uncertainty is particularly important when considering treatments intended for otherwise healthy individuals or for prolonged periods.
Certain therapies may be inappropriate in pregnancy or breastfeeding, active malignancy, uncontrolled metabolic disease, or other medical conditions. Contraindications should be determined for the specific therapy rather than applied uniformly to every peptide.
Medical supervision and appropriate follow-up are therefore important whenever prescription peptide therapy is used.
Who Might Consider Discussing Peptide Therapy With a Clinician?
There is no universal “ideal candidate” for peptide therapy.
A discussion may be reasonable when a patient has a defined clinical or performance concern for which a particular peptide-based therapy has a plausible mechanism and an evidence base sufficient to justify consideration.
Depending on the specific therapy, those conversations may involve areas such as:
- Hormonal or metabolic health
- Body composition
- Recovery and physical performance
- Specific age-associated physiological changes
- Other defined medical concerns for which peptide-based medications have been studied
The key question should not be: “Am I a candidate for peptides?”
Instead, it should be: “Is there a specific therapy with sufficient evidence, an acceptable safety profile, and a reasonable clinical rationale for my particular situation?”
That distinction is central to responsible peptide prescribing.
The Bottom Line
Peptides are important biological signaling molecules, and peptide-based medications already play established roles throughout medicine. Their potential applications in longevity medicine are also an active area of research.
At the same time, the evidence is not uniform. Some peptide therapies are supported by substantial human clinical research, while others remain investigational and are supported primarily by mechanistic, preclinical, observational, or early-stage clinical evidence.
For patients interested in peptide therapy, the most important considerations are:
- Evaluate each therapy individually rather than treating “peptides” as a single category.
- Understand the difference between biological plausibility and demonstrated human clinical benefit.
- Know whether a therapy is FDA-approved, prescribed off-label, compounded, or investigational.
- Consider potential benefits alongside known and unknown risks.
- Use medical therapies as an addition to—not a replacement for—the foundations of preventive health and longevity.
- Make treatment decisions through individualized assessment and appropriate medical monitoring.
Peptide science represents a compelling and rapidly developing area of medicine. The goal at Aerwell is not to assume that every promising mechanism translates into a meaningful therapy, but to evaluate emerging interventions thoughtfully—using the best available evidence while remaining transparent about what is known, what remains uncertain, and where the science is still evolving.
Sources
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001.
- Smith RG, Sun Y, Betancourt L, Asnicar M. Growth hormone secretagogues: prospects and potential pitfalls. Best Practice & Research Clinical Endocrinology & Metabolism. 2004;18(3):333–347. doi:10.1016/j.beem.2004.04.001.
- Kim SJ, Miller B, Kumagai H, et al. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2021;43(3):1113–1121. doi:10.1007/s11357-020-00262-5.
- Miller B, Kim SJ, Kumagai H, Yen K. Mitochondria-derived peptides in aging and healthspan. Journal of Clinical Investigation. 2022;132(9). doi:10.1172/JCI158449.
- U.S. Food and Drug Administration. Human Drug Compounding. Current federal information regarding compounded medications and the regulatory framework governing human drug compounding.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Information for patients and healthcare professionals regarding compounded drugs, including differences between compounded and FDA-approved medications.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current FDA information regarding bulk drug substances, including certain peptide substances, identified as presenting potential safety concerns.
A Note About the Evidence
Research involving peptide-based therapies is evolving rapidly. The quality and quantity of evidence vary substantially among individual compounds, ranging from FDA-approved therapies supported by extensive clinical trials to investigational peptides for which human safety and efficacy data remain limited.
The inclusion of a study or regulatory source in this article does not establish the safety or effectiveness of any specific peptide therapy for longevity purposes.
This article is provided for educational purposes only and is not intended as individual medical advice. The potential benefits, risks, regulatory status, and evidence supporting peptide therapies vary by medication and indication.
Treatment decisions should be made individually with an appropriately licensed healthcare professional.
